瘙痒作为过敏性疾病的一种典型症状，其量化评估尚存在一定空白。视觉模拟评分和峰值瘙痒数字评价量表可快速了解主观上的瘙痒程度，而多维度量表将皮肤损伤、睡眠障碍等伴发问题纳入考察指标，更加全面具体。抓挠作为机体的行为反馈，可反映瘙痒的严重程度。视频监控、声学监控、加速度计是抓挠计数的主要方法，人工智能和生物工程的发展为辅助工具的开发提供了新的可能。血清IL-31、血浆颗粒酶B、平均血小板体积等生物标志物和瘙痒程度的关联已被证实，随着基础和临床实验的完善，更充分的临床证据有望建立。本文对相关要点进行综述。

[1] YANG T B,KIM B S.Pruritus in allergy and immunology[J].J Allergy Clin Immunol,2019,144(2):353-360.
[2] CHANG H Y,SEO J H,KIM H Y,et al.Allergic diseases in preschoolers are associated with psychological and behavioural problems[J].Allergy Asthma Immunol Res,2013,5(5):315-321.
[3] JANG Y H,KIM S M,EUN D H,et al.Validity and reliability of itch assessment scales for chronic pruritus in adults:a prospective multicenter study[J].J Am Acad Dermatol,2020,82(1):80-86.
[4] YOSIPOVITCH G,REANEY M,MASTEY V,et al.Peak pruritus numerical rating scale:psychometric validation and responder definition for assessing itch in moderate-to-severe atopic dermatitis[J].Br J Dermatol,2019,181(4):761-769.
[5] 中国医师协会皮肤科分会变态反应性疾病专业委员会.慢性瘙痒管理指南(2018版)[J].中华皮肤科杂志，2018，51(7)：481-485.
[6] HARDAS A,SINGH N,MOHANTY A,et al.Efficacy of montelukast in preventing seasonal recurrence of vernal keratoconjunctivitis in children[J].Eye(Lond),2022,36(5):978-984.
[7] YOSHINO T,HORIBA Y,MIMURA M,et al.Exploring standardized scales and serum biomarkers to evaluate changes in pruritus due to eczema after Japanese kampo treatment:a prospective case series[J].Complement Med Res,2022,29(5):373-381.
[8] LESHEM Y A,CHALMERS J R,APFELBACHER C,et al.Measuring atopic eczema control and itch intensity in clinical practice:a consensus statement from the harmonising outcome measures for eczema in clinical practice(HOME-CP) initiative[J].JAMA Dermatol,2022,158(12):1429-1435.
[9] CUKROWSKA B,CEREGRA A,MACIORKOWSKA E,et al.The effectiveness of probiotic lactobacillus rhamnosus and lactobacillus casei strains in children with atopic dermatitis and cow's milk protein allergy:a multicenter,randomized,double blind,placebo controlled study[J].Nutrients,2021,13(4):1169.
[10] SIMPSON E L,DE BRUIN-WELLER M,ECKERT L,et al.Responder threshold for patient-oriented eczema measure(POEM) and children's dermatology life quality index(CDLQI) in adolescents with atopic dermatitis[J].Dermatol Ther(Heidelb),2019,9(4):799-805.
[11] HALL R,LEBWOHL M G,BUSHMAKIN A G,et al.Development and content validation of pruritus and symptoms assessment for atopic dermatitis(PSAAD) in adolescents and adults with moderate-to-severe AD[J].Dermatol Ther(Heidelb),2021,11(1):221-233.
[12] STEIN GOLD L F,SPELMAN L,SPELLMAN M C,et al.A phase 2,randomized,controlled,dose-ranging study evaluating crisaborole topical ointment,0.5%and 2% in adolescents with mild to moderate atopic dermatitis[J].J Drugs Dermatol,2015,14(12):1394-1399.
[13] GIL Y,SIMPSON E L,BUSHMAKIN A G,et al.Assessment of pruritus in atopic dermatitis:validation of the severity of pruritus scale(SPS)[J].Itch,2018,3(2):e13.
[14] EICHENFIELD L F,YOSIPOVITCH G,STEIN GOLD L F,et al.Improvement in disease severity and pruritus outcomes with crisaborole ointment,2%,by baseline atopic dermatitis severity in children and adolescents with mild-to-moderate atopic dermatitis[J].Pediatr Dermatol,2020,37(6):1030-1037.
[15] SIMPSON E L,TOM W L,BUSHMAKIN A G,et al.Relationship among treatment,pruritus,investigator's static global assessment,and quality of life in patients with atopic dermatitis[J].Dermatol Ther(Heidelb),2021,11(2):587-598.
[16] STÄNDER S,YOSIPOVITCH G,BUSHMAKIN A G,et al.Examining the association between pruritus and quality of life in patients with atopic dermatitis treated with crisaborole[J].J Eur Acad Dermatol Venereol,2019,33(9):1742-1746.
[17] 唐珏，姚志荣.特应性皮炎瘙痒机制及相关治疗研究进展[J].协和医学杂志，2022，13(3)：473-479.
[18] SMITH M P,LY K,THIBODEAUX Q,et al.Emerging methods to objectively assess pruritus in atopic dermatitis[J].Dermatol Ther(Heidelb),2019,9(3):407-420.
[19] CHE D N,CHO B O,SHIN J Y,et al.Fisetin inhibits IL-31 production in stimulated human mast cells:possibilities of fisetin being exploited to treat histamine-independent pruritus[J].Life Sci,2018,201:121-129.
[20] PARK I,LEE K,BISHAYEE K,et al.Machine-learning based automatic and real-time detection of mouse scratching behaviors[J].Exp Neurobiol,2019,28(1):54-61.
[21] YU H,XIONG J,YE A Y,et al.Scratch-AID,a deep learning-based system for automatic detection of mouse scratching behavior with high accuracy[J].Elife,2022,11:e84042.
[22] NORO Y,OMOTO Y,UMEDA K,et al.Novel acoustic evaluation system for scratching behavior in itching dermatitis:rapid and accurate analysis for nocturnal scratching of atopic dermatitis patients[J].J Dermatol,2014,41(3):233-238.
[23] CHUN K S,KANG Y J,LEE J Y,et al.A skin-conformable wireless sensor to objectively quantify symptoms of pruritus[J].Sci Adv,2021,7(18):eabf9405.
[24] BENJAMIN K,WATERSTON K,RUSSELL M,et al.The development of an objective method for measuring scratch in children with atopic dermatitis suitable for clinical use[J].J Am Acad Dermatol,2004,50(1):33-40.
[25] IKOMA A,EBATA T,CHANTALAT L,et al.Measurement of nocturnal scratching in patients with pruritus using a smartwatch:initial clinical studies with the itch tracker app[J].Acta Derm Venereol,2019,99(3):268-273.
[26] KOGURE T,EBATA T.Activity during sleep measured by a sheet-shaped body vibrometer and the severity of atopic dermatitis in adults:a comparison with wrist actigraphy[J].J Clin Sleep Med,2018,14(2):199-204.
[27] MOLLANAZAR N K,SMITH P K,YOSIPOVITCH G.Mediators of chronic pruritus in atopic dermatitis:getting the itch out?[J].Clin Rev Allergy Immunol,2016,51(3):263-292.
[28] KABASHIMA K,MATSUMURA T,KOMAZAKI H,et al.Nemolizumab plus topical agents in patients with atopic dermatitis(AD) and moderate-to-severe pruritus provide improvement in pruritus and signs of AD for up to 68 weeks:results from two phase Ⅲ,long-term studies[J].Br J Dermatol,2022,186(4):642-651.
[29] BYEON J H,YOON W,AHN S H,et al.Correlation of serum interleukin-31 with pruritus and blood eosinophil markers in children with atopic dermatitis[J].Allergy Asthma Proc,2020,41(1):59-65.
[30] TIRADO-SÁNCHEZ A,BONIFAZ A,PONCE-OLIVERA R M.Serum gastrin-releasing peptide levels correlate with disease severity and pruritus in patients with atopic dermatitis[J].Br J Dermatol,2015,173(1):298-300.
[31] KAMATA Y,KIMURA U,MATSUDA H,et al.Relationships among plasma granzyme B level,pruritus and dermatitis in patients with atopic dermatitis[J].J Dermatol Sci,2016,84(3):266-271.
[32] 陆延娜，马晓红.特应性皮炎患者平均血小板体积及其与瘙痒程度的相关性[J].血栓与止血学，2022，28(3)：983-984,987.
[33] FITOUSSI J,VIRASSAMYNAIK S,CALLEJON S,et al.Inhibition of thymic stromal lymphopoietin production to improve pruritus and quality of life in infants and children with atopic dermatitis[J].J Cosmet Dermatol,2020,19(8):2061-2069.
[34] 董江川.胸腺基质淋巴细胞生成素对血小板功能的影响及其机制研究[D].武汉：华中科技大学，2014.
[35] OETJEN L K,MACK M R,FENG J,et al.Sensory neurons Co-opt classical immune signaling pathways to mediate chronic Itch[J].Cell,2017,171(1):217-228.
[36] 任红润，戴丽，邵倩，等.人文关怀视角下的专科医院健康促进医院工作实践与体会[J].现代医学，2022，50(S1)：70-74.
[37] RODRIGUES L,EKUNDI-VALENTIM E,FLORENZANO J,et al.Protective effects of exogenous and endogenous hydrogen sulfide in mast cell-mediated pruritus and cutaneous acute inflammation in mice[J].Pharmacol Res,2017,115:255-266.